(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.34%) $0.935
(0.56%) $11.01
(0.12%) $0.800
(0.00%) $92.17
3 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 6.71%
@ $64.15
Utstedt: 26 apr 2024 @ 19:48
Avkastning: -0.14%
Forrige signal: apr 25 - 21:50
Forrige signal:
Avkastning: 2.40 %
Live Chart Being Loaded With Signals
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide...
Stats | |
---|---|
Dagens volum | 946 213 |
Gjennomsnittsvolum | 1.09M |
Markedsverdi | 10.07B |
EPS | $0 ( 2024-02-01 ) |
Neste inntjeningsdato | ( $0.460 ) 2024-05-01 |
Last Dividend | $0.0800 ( 2023-11-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | 46.09 |
ATR14 | $1.869 (2.91%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Bohnen Shane | Sell | 2 259 | Restricted Stock Units |
2024-04-03 | Bohnen Shane | Buy | 2 259 | Common Stock |
2024-04-03 | Bohnen Shane | Sell | 747 | Common Stock |
2024-03-07 | Nusse Roeland | Sell | 10 400 | Common Stock |
2024-02-01 | Geist William | Sell | 1 111 | Common Stock |
INSIDER POWER |
---|
3.66 |
Last 99 transactions |
Buy: 1 979 464 | Sell: 2 067 622 |
Volum Korrelasjon
Bio-Techne Corp Korrelasjon
10 Mest negative korrelasjoner | |
---|---|
SVAC | -0.935 |
TLGT | -0.901 |
RMRM | -0.897 |
PAIC | -0.887 |
FEYE | -0.864 |
SVOK | -0.851 |
TEAM | -0.842 |
UBOH | -0.834 |
TRIN | -0.833 |
INZY | -0.827 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Bio-Techne Corp Korrelasjon - Valuta/Råvare
Bio-Techne Corp Økonomi
Annual | 2023 |
Omsetning: | $1.14B |
Bruttogevinst: | $769.82M (67.72 %) |
EPS: | $1.810 |
FY | 2023 |
Omsetning: | $1.14B |
Bruttogevinst: | $769.82M (67.72 %) |
EPS: | $1.810 |
FY | 2022 |
Omsetning: | $1.11B |
Bruttogevinst: | $756.50M (68.42 %) |
EPS: | $1.730 |
FY | 2021 |
Omsetning: | $931.03M |
Bruttogevinst: | $632.85M (67.97 %) |
EPS: | $0.867 |
Financial Reports:
No articles found.
Bio-Techne Corp Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0625 | 2008-10-30 |
Last Dividend | $0.0800 | 2023-11-09 |
Next Dividend | $0 | N/A |
Payout Date | 2023-11-24 | |
Next Payout Date | N/A | |
# dividends | 61 | -- |
Total Paid Out | $4.63 | -- |
Avg. Dividend % Per Year | 0.25% | -- |
Score | 4.89 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.04 | |
Div. Directional Score | 8.94 | -- |
Year | Amount | Yield |
---|---|---|
2008 | $0.0625 | 0.37% |
2009 | $0.253 | 1.57% |
2010 | $0.263 | 1.53% |
2011 | $0.273 | 1.64% |
2012 | $0.285 | 1.66% |
2013 | $0.303 | 1.75% |
2014 | $0.313 | 1.33% |
2015 | $0.320 | 1.40% |
2016 | $0.320 | 1.45% |
2017 | $0.320 | 1.25% |
2018 | $0.320 | 0.97% |
2019 | $0.320 | 0.90% |
2020 | $0.320 | 0.58% |
2021 | $0.320 | 0.41% |
2022 | $0.320 | 0.26% |
2023 | $0.320 | 0.39% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.196 | 1.500 | 6.08 | 9.13 | [0 - 0.5] |
returnOnAssetsTTM | 0.0821 | 1.200 | 7.26 | 8.72 | [0 - 0.3] |
returnOnEquityTTM | 0.115 | 1.500 | 9.84 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.225 | -1.000 | 7.75 | -7.75 | [0 - 1] |
currentRatioTTM | 4.37 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.54 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.962 | 1.500 | 5.77 | 8.65 | [0.2 - 2] |
debtRatioTTM | 0.203 | -1.500 | 6.61 | -9.91 | [0 - 0.6] |
interestCoverageTTM | 20.76 | 1.000 | 3.42 | 3.42 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.755 | 2.00 | 9.42 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.431 | 2.00 | 9.28 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.283 | -1.500 | 8.87 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.671 | 1.000 | 2.15 | 2.15 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.235 | 1.000 | 7.31 | 7.31 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.497 | 1.000 | 8.35 | 8.35 | [0.2 - 2] |
assetTurnoverTTM | 0.419 | 0.800 | -0.538 | -0.430 | [0.5 - 2] |
Total Score | 11.84 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 45.02 | 1.000 | 5.55 | 0 | [1 - 100] |
returnOnEquityTTM | 0.115 | 2.50 | 9.90 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.431 | 2.00 | 9.52 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.500 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.755 | 2.00 | 9.42 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.225 | 1.500 | 7.75 | -7.75 | [0 - 1] |
pegRatioTTM | 0.335 | 1.500 | -1.100 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.241 | 1.000 | 6.46 | 0 | [0.1 - 0.5] |
Total Score | 6.04 |
Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.